Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results.

7590 Background: Linifanib (ABT-869), a novel orally active VEGF/PDGF RTK inhibitor, had single-agent activity in pts with advanced solid tumors including NSCLC. Methods: This open-label multicente...